Knowles cuts its target the day before earnings

KN dropped 6.2% over the past week to $34.32, a move that lands the stock inside a broadly weak peer group but draws particular attention one day before its Q3 earnings release, scheduled for October 22.

The most concrete development this week came from the Street. Susquehanna's Christopher Rolland lowered his price target on KN to $35 from $40 on October 21, keeping his Neutral rating in place. That cut is notable: it brings his target almost level with the current share price, leaving virtually no implied upside from the firm that has covered this stock most consistently over the past three years. The contrast with the prior cycle is sharp. Rolland raised his target to $40 following the July print, and Baird's Tristan Gerra lifted his to $39 with an Outperform rating in April. The consensus mean price target is now $42.50, but with Rolland's freshly cut $35 sitting at the low end, the Street's constructive view is becoming harder to square with where the stock is trading.

The lending market tells a calmer story than the price action might suggest. Short interest runs at roughly 5% of free float, up about 1% on the week, but availability is exceptionally wide at 2,442%, meaning there are more than twenty-four times as many shares available to borrow as are currently lent out. Borrow costs at 0.57% are low by any measure, up around 11% on the week but still far from the kind of level that would signal a disorderly squeeze or forced covering. The ORTEX short score of 43 sits in the lower half of the scale, consistent with moderate rather than extreme short-side pressure. Availability peaked at just above 5.6% utilization twelve months ago and has been loose all year, so the lending market is not adding urgency to the bear case.

Options positioning has shifted more noticeably. The put/call ratio has climbed to 0.168, close to two standard deviations above its 20-day average of 0.112, the most defensive reading in roughly a month. That shift happened across the past week, coinciding with the stock's decline and ahead of tomorrow's print. The 52-week range for the PCR runs from 0.007 to 0.324, so the current reading is elevated without being at an extreme.

Institutional ownership shows a few interesting directional signals from recent filings. T. Rowe Price added 1.64 million shares in the quarter to September, bringing its position to just over 2% of shares outstanding. Goldman Sachs Asset Management added 752,000 shares and crossed the 5% threshold, filing a fresh 13G in August. Putnam initiated a new position of 1.5 million shares. On the other side, Ariel Investments cut its stake by 512,000 shares as of June, and Franklin Mutual Advisers reduced from 5.3% to 1.5% of the class in a filing from January. On the insider side, virtually all recent Form 4 activity has been selling, including CEO Jeffrey Niew selling around $7.9 million worth of stock across two days in August, all under pre-arranged 10b5-1 plans. Discretionary selling is absent from recent filings, which limits the read-across, but the volume of planned sales at prices around $38 to $39 is at least worth noting given where the stock trades today.

The prior two earnings prints both produced positive one-day moves, 5.9% in April's Q1 report and 2.6% after the Q2 release in July. The five-day window after Q2 gave back most of that gain, but the immediate reaction has been constructive in recent quarters. Whether the pattern holds matters more given Rolland's target now barely clears the current price: a muted or negative reaction tomorrow would put significant pressure on the bull case that still has a consensus target of $42.50.

The specific thing to watch is tomorrow evening's Q3 report. The Rolland target cut to $35 from $40, filed the morning before the print, sets a precise marker: either the results provide a reason to revisit that figure upward, or the Street's most cautious voice is confirmed.